Serum IL-6: A biomarker in childhood asthma?

Daniel J. Jackson; Leonard B. Bacharier; Agustin Calatroni; Michelle A. Gill; Jack Hu; Andrew H. Liu; Lisa M. Wheatley; James E. Gern; Rebecca S. Gruchalla; Gurjit K. Khurana Hershey; Meyer Kattan; Carolyn M. Kercsmar; Haejin Kim; George T. O'Connor; Shilpa Patel; Jacqueline A. Pongracic; Robert A. Wood; William W. Busse

doi:10.1016/j.jaci.2020.01.021

Serum IL-6: A biomarker in childhood asthma?

Daniel J. Jackson, Leonard B. Bacharier, Agustin Calatroni, Michelle A. Gill, Jack Hu, Andrew H. Liu, Lisa M. Wheatley, James E. Gern, Rebecca S. Gruchalla, Gurjit K. Khurana Hershey, Meyer Kattan, Carolyn M. Kercsmar, Haejin Kim, George T. O'Connor, Shilpa Patel, Jacqueline A. Pongracic, Robert A. Wood, William W. Busse

Pediatrics

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Original language	English (US)
Pages (from-to)	1701-1704.e3
Journal	Journal of Allergy and Clinical Immunology
Volume	145
Issue number	6
DOIs	https://doi.org/10.1016/j.jaci.2020.01.021
State	Published - Jun 2020

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1016/j.jaci.2020.01.021

Cite this

Jackson, D. J., Bacharier, L. B., Calatroni, A., Gill, M. A., Hu, J., Liu, A. H., Wheatley, L. M., Gern, J. E., Gruchalla, R. S., Khurana Hershey, G. K., Kattan, M., Kercsmar, C. M., Kim, H., O'Connor, G. T., Patel, S., Pongracic, J. A., Wood, R. A., & Busse, W. W. (2020). Serum IL-6: A biomarker in childhood asthma? Journal of Allergy and Clinical Immunology, 145(6), 1701-1704.e3. https://doi.org/10.1016/j.jaci.2020.01.021

@article{1b09602e9b584b388d1f3adf77e54abc,

title = "Serum IL-6: A biomarker in childhood asthma?",

author = "Jackson, {Daniel J.} and Bacharier, {Leonard B.} and Agustin Calatroni and Gill, {Michelle A.} and Jack Hu and Liu, {Andrew H.} and Wheatley, {Lisa M.} and Gern, {James E.} and Gruchalla, {Rebecca S.} and {Khurana Hershey}, {Gurjit K.} and Meyer Kattan and Kercsmar, {Carolyn M.} and Haejin Kim and O'Connor, {George T.} and Shilpa Patel and Pongracic, {Jacqueline A.} and Wood, {Robert A.} and Busse, {William W.}",

note = "Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) 1UM1AI114271-01. Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) 1UM1AI114271-01. Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Disclosure of potential conflict of interest: D. J. Jackson reports receiving grants from the National Institutes of Health (NIH) and GlaxoSmithKline; personal fees for the Data Safety Monitoring Board from Pfizer; and fees for consulting from Novartis, Sanofi-Regeneron, Vifor Pharma, and Astra Zeneca. L. B. Bacharier reports personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, and royalties from Up To Date. W. W. Busse reports grants from the NIH-National Institute of Allergy and Infectious Diseases, during the conduct of the study; personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Boston Scientific, Regeneron, Arrowhead, resTORbio, Medscape, Gossamer Bio, Genentech, and Elsevier, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.",

year = "2020",

month = jun,

doi = "10.1016/j.jaci.2020.01.021",

language = "English (US)",

volume = "145",

pages = "1701--1704.e3",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "6",

}

Jackson, DJ, Bacharier, LB, Calatroni, A, Gill, MA, Hu, J, Liu, AH, Wheatley, LM, Gern, JE, Gruchalla, RS, Khurana Hershey, GK, Kattan, M, Kercsmar, CM, Kim, H, O'Connor, GT, Patel, S, Pongracic, JA, Wood, RA & Busse, WW 2020, 'Serum IL-6: A biomarker in childhood asthma?', Journal of Allergy and Clinical Immunology, vol. 145, no. 6, pp. 1701-1704.e3. https://doi.org/10.1016/j.jaci.2020.01.021

TY - JOUR

T1 - Serum IL-6

T2 - A biomarker in childhood asthma?

AU - Jackson, Daniel J.

AU - Bacharier, Leonard B.

AU - Calatroni, Agustin

AU - Gill, Michelle A.

AU - Hu, Jack

AU - Liu, Andrew H.

AU - Wheatley, Lisa M.

AU - Gern, James E.

AU - Gruchalla, Rebecca S.

AU - Khurana Hershey, Gurjit K.

AU - Kattan, Meyer

AU - Kercsmar, Carolyn M.

AU - Kim, Haejin

AU - O'Connor, George T.

AU - Patel, Shilpa

AU - Pongracic, Jacqueline A.

AU - Wood, Robert A.

AU - Busse, William W.

N1 - Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) 1UM1AI114271-01. Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Funding Information: This project has been funded in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) 1UM1AI114271-01. Additional support was provided by the National Center for Research Resources (NCRR), and the National Center for Advancing Translational Sciences (NCATS), NIH (under grant nos. NCRR/NIH UL1TR000451, UL1RR025780, UL1TR000075 Q1 and NCATS/NIH UL1TR000154, UL1TR001082, UL1TR000077-04, UL1TR000040, UL1TR000150, and UL1TR001105). Disclosure of potential conflict of interest: D. J. Jackson reports receiving grants from the National Institutes of Health (NIH) and GlaxoSmithKline; personal fees for the Data Safety Monitoring Board from Pfizer; and fees for consulting from Novartis, Sanofi-Regeneron, Vifor Pharma, and Astra Zeneca. L. B. Bacharier reports personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia. R. A. Wood receives grant support from the NIH, Astellas, Aimmune, DBV, Sanofi, and Regeneron, and royalties from Up To Date. W. W. Busse reports grants from the NIH-National Institute of Allergy and Infectious Diseases, during the conduct of the study; personal fees from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Boston Scientific, Regeneron, Arrowhead, resTORbio, Medscape, Gossamer Bio, Genentech, and Elsevier, outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2020/6

Y1 - 2020/6

UR - http://www.scopus.com/inward/record.url?scp=85080107778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080107778&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2020.01.021

DO - 10.1016/j.jaci.2020.01.021

M3 - Article

C2 - 32004524

AN - SCOPUS:85080107778

SN - 0091-6749

VL - 145

SP - 1701-1704.e3

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 6

ER -

Serum IL-6: A biomarker in childhood asthma?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this